SCM
EFTRW

Saba Capital Management’s eFFECTOR Therapeutics, Inc. Warrant EFTRW Stock Holding History

Saba Capital Management’s Portfolio EFTRW Stock Details EFTRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-34,836
Closed -$21K – 470
2021
Q1 		$21K Buy
+34,836
New +$33.6K ﹤0.01% 422

Other funds holding EFTRW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.1% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
QGA
Q Global Advisors Fort Worth, Texas $113M AUM 20.91% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Saba Capital Management's EFTRW Position: Q2 2021 in Review

Saba Capital Management sold out of eFFECTOR Therapeutics, Inc. Warrant (EFTRW) in Q2 2021, closing a stake of 34,836 shares — an estimated $21K sold.

Saba Capital Management first reported a position in EFTRW in Q1 2021 and held it in 1 quarter. The position peaked at $21K in Q1 2021. 38 funds tracked by Wall St. Rank hold EFTRW as of Q2 2021.

  • Saba Capital Management reported no remaining eFFECTOR Therapeutics, Inc. Warrant position as of Q2 2021 after selling out during the quarter.
  • Saba Capital Management sold 34,836 eFFECTOR Therapeutics, Inc. Warrant shares in Q2 2021, an estimated $21K.
  • Saba Capital Management first reported a position in eFFECTOR Therapeutics, Inc. Warrant in Q1 2021 and held it in 1 quarter.
  • Saba Capital Management's eFFECTOR Therapeutics, Inc. Warrant position peaked at $21K in Q1 2021.
  • 38 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Warrant as of Q2 2021.

Based on Saba Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.